Ikena Oncology Inc IKNA:NASDAQ

RT Quote | NASDAQ | USD
Last | 05/17/21 EDT
17.41quote price arrow down-0.92 (-5.02%)
Volume
134,330
52 week range
14.16 - 37.61

...

Loading . . .
  • Open18.52
  • Day High19.69
  • Day Low16.97
  • Prev Close17.41
  • 52 Week High37.61
  • 52 Week High Date03/26/21
  • 52 Week Low14.16
  • 52 Week Low Date04/12/21

Key Stats

  • Market Cap602.21M
  • Shares Out34.59M
  • 10 Day Average Volume0.20M
  • Dividend-
  • Dividend Yield-
  • Beta
  • YTD % Change-

KEY STATS

  • Open18.52
  • Day High19.69
  • Day Low16.97
  • Prev Close17.41
  • 52 Week High37.61
  • 52 Week High Date03/26/21
  • 52 Week Low14.16
  • 52 Week Low Date04/12/21
  • Market Cap602.21M
  • Shares Out34.59M
  • 10 Day Average Volume0.20M
  • Dividend-
  • Dividend Yield-
  • Beta
  • YTD % Change-

RATIOS/PROFITABILITY

  • EPS (TTM)-1.28
  • P/E (TTM)-13.61
  • Fwd P/E (NTM)-10.21
  • EBITDA (MRQ)-44.194M
  • ROE (MRQ)-
  • Revenue (MRQ)9.19M
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-481.36%
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Ikena Oncology Inc

There is no recent news for this security.

Latest From Our Partners

There is no recent news for this security.

Profile

MORE
Ikena Oncology, Inc. is a targeted oncology company. The Company is focused on developing cancer therapies targeting signaling pathways that drive the formation and spread of cancer. Its lead targeted oncology product candidate, IK-930, is an oral small molecule inhibitor of the transcriptional enhanced associate domain (TEAD), transcription factor in the Hippo signaling pathway. It intends to pursue clinical development of IK-930 across a range of tumor types with known...
Ronald Renaud Jr.
Chairman
Mark Manfredi Ph.D.
President
Douglas Carlson
Chief Financial Officer
Karen McGovern Ph.D.
Vice President
Address
50 Northern Ave.
Boston, MA
02210
United States